Investors flocked to the so-called "bomb dividends." RedcapTour announced a dividends plan of 2,000 won per common share the ...

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for rare, common, chronic and age-associated diseases, announced that it has ...

Founded by Professors Omar Abudayyeh, Jonathan Gootenberg, and Patrick Hsu leveraging novel AI models and technologies for designing, building, and delivering RNA- Raised $9M in seed funding from ...

The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...

To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Orum Therapeutics sets public offering price at 20,000 won, below target range Orum Therapeutics announces lower-than-expected public offering price as subscription period approaches ...

Faculty of Life Sciences, Department of Pharmaceutical Sciences, Laboratory of Macromolecular Cancer Therapeutics (MMCT), University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.